Trial Profile
A randomised, double blind trial to assess the morphological and biological effects with Arimidex [anastrazole], compared to placebo when used as neoadjuvant treatment for patients with endometrial cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Oct 2005
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary)
- Indications Endometrial cancer
- Focus Registrational; Therapeutic Use
- 27 Oct 2005 New trial record.